Bone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
14 patients experienced tumor recurrence or death.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[RESULTS] Median DFS was 22.58 months, and 14 patients experienced tumor recurrence or death.
[BACKGROUND] Non-small cell lung cancer (NSCLC) is the most common lung cancer, and surgery is the primary curative treatment approach.
APA
Zhou F, Li P, et al. (2026). Bone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy.. World journal of surgical oncology, 24(1), 69. https://doi.org/10.1186/s12957-025-04186-2
MLA
Zhou F, et al.. "Bone mineral density as a prognostic marker in patients with non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy.." World journal of surgical oncology, vol. 24, no. 1, 2026, pp. 69.
PMID
41508009
Abstract
[BACKGROUND] Non-small cell lung cancer (NSCLC) is the most common lung cancer, and surgery is the primary curative treatment approach. Recently, neoadjuvant immunotherapy combined with chemotherapy (NICT) has become an important strategy. However, not all patients benefit, underscoring the need for reliable prognostic biomarkers. Bone mineral density (BMD) is associated with the prognosis of various cancers. This study explores the relationship between computed tomography (CT)-derived BMD and prognosis in NSCLC patients treated with NICT.
[METHODS] 101 stage IIA-IIIB NSCLC patients undergoing NICT and R0 resection surgery at our institution were included. Chest CT, highly correlated with dual-energy X-ray absorptiometry (DXA), was used to analyze the baseline and preoperative T10, T12, and L1 BMD. We analyzed disease-free survival (DFS) and overall survival (OS) through Kaplan-Meier survival curves, cox regression, and restricted cubic splines (RCS). Major pathologic response (MPR) and pathologic complete response (pCR) were compared through logistic regression. Subgroup analysis and sensitivity analysis were conducted to evaluate the accuracy of the results.
[RESULTS] Median DFS was 22.58 months, and 14 patients experienced tumor recurrence or death. A significant decrease in BMD was observed at the T10, T12, and L1 vertebrae following NICT ( < 0.001). Patients with higher baseline and preoperative L1 BMD had significantly improved DFS ( = 0.002, = 0.002). The prognostic value for BMD was confirmed through RCS analysis and multivariate Cox-regression analysis, as well as sensitivity analysis. Subgroup analysis revealed that the effect of L1 BMD on DFS showed significant interaction in age and MPR groups, suggesting age specific and treatment-response specific differences.
[CONCLUSION] Both baseline and preoperative L1 BMD are valuable, readily available, and independent prognostic biomarkers for DFS in NSCLC patients receiving NICT.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12957-025-04186-2.
[METHODS] 101 stage IIA-IIIB NSCLC patients undergoing NICT and R0 resection surgery at our institution were included. Chest CT, highly correlated with dual-energy X-ray absorptiometry (DXA), was used to analyze the baseline and preoperative T10, T12, and L1 BMD. We analyzed disease-free survival (DFS) and overall survival (OS) through Kaplan-Meier survival curves, cox regression, and restricted cubic splines (RCS). Major pathologic response (MPR) and pathologic complete response (pCR) were compared through logistic regression. Subgroup analysis and sensitivity analysis were conducted to evaluate the accuracy of the results.
[RESULTS] Median DFS was 22.58 months, and 14 patients experienced tumor recurrence or death. A significant decrease in BMD was observed at the T10, T12, and L1 vertebrae following NICT ( < 0.001). Patients with higher baseline and preoperative L1 BMD had significantly improved DFS ( = 0.002, = 0.002). The prognostic value for BMD was confirmed through RCS analysis and multivariate Cox-regression analysis, as well as sensitivity analysis. Subgroup analysis revealed that the effect of L1 BMD on DFS showed significant interaction in age and MPR groups, suggesting age specific and treatment-response specific differences.
[CONCLUSION] Both baseline and preoperative L1 BMD are valuable, readily available, and independent prognostic biomarkers for DFS in NSCLC patients receiving NICT.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12957-025-04186-2.
같은 제1저자의 인용 많은 논문 (5)
- Prognostic Value of MRI-Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST, LI-RADS TRA Version 2017, and LI-RADS Radiation TRA Version 2024.
- Evaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines.
- Deoxypodophyllotoxin inhibits lung adenocarcinoma growth through regulation of FOXO1 nuclear translocation.
- Asiatic Acid Ameliorates MNNG-Induced Chronic Atrophic Gastritis by Inhibiting the Activation of the HRAS/PI3K/AKT/GSK3β Signaling Axis.
- Integrative machine learning analysis suggests novel molecular targets for liver cancer diagnosis and therapy.